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Abstract
 
Vaccination with dendritic cells (DCs) presenting tumor antigens induces primary immune re-
sponse or amplifies existing cytotoxic antitumor T cell responses. This study documents that
antitumor treatment with DCs may cause severe autoimmune disease when the tumor antigens
are not tumor-specific but are also expressed in peripheral nonlymphoid organs. Growing tu-
mors with such shared tumor antigens that were, at least initially, strictly located outside of sec-
ondary lymphoid organs were successfully controlled by specific DC vaccination. However,
antitumor treatment was accompanied by fatal autoimmune disease, i.e., autoimmune diabetes
in transgenic mice expressing the tumor antigen also in pancreatic 
 
b
 
 islet cells or by severe ar-
teritis, myocarditis, and eventually dilated cardiomyopathy when arterial smooth muscle cells
and cardiomyocytes expressed the transgenic tumor antigen. These results reveal the delicate
balance between tumor immunity and autoimmunity and therefore point out important limita-
tions for the use of not strictly tumor-specific antigens in antitumor vaccination with DCs.
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Introduction
 
A large number of tumor antigens has been identified, and
antitumor responses against these antigens can be elicited in
mice or humans (1–4). Tumor antigens most suitable for
immunotherapy are, ideally, the strictly tumor-specific an-
tigens that are shared by different tumors or mutated pro-
teins expressed uniquely by tumor cells (2). However,
many tumor antigens that are shared with other tissues are
recognized by tumor-specific CTLs, such as the melano-
cyte differentiation antigen tyrosinase-related protein 2
(TRP-2; references 5 and 6) or the antigen p53 (7), which
is specifically overexpressed in tumors. Therefore, for cer-
tain tumor antigens, an efficient immune response may po-
tentially be harmful, because immunity against self-antigens
may cause autoimmunity. Indeed, efficient tumor control
in human patients may be associated with autoimmune phe-
nomena, e.g., antimelanoma immunity that sometimes cor-
relates with vitiligo (8), certain gynecological tumors that ap-
pear to induce paraneoplastic cerebellar degeneration (9), or
Wegener’s granulomatosis, which is often associated with re-
nal cell carcinoma (10). It is therefore important to assess
the potential sequelae of immunity against tumor antigens
that are also expressed by normal cells of peripheral organs,
i.e., antigens that are located strictly outside of the immune
system and are shared between tumors and normal host tis-
sues. It has been shown that such antigens are largely ig-
nored by T cells but can be reacted against if sufficient anti-
gen reaches secondary lymphoid organs during a sufficient
time period (11).
Dendritic cells (DCs)
 
1
 
 are potent immunostimulatory
cells facilitating antigen transport to lymphoid tissues and
efficient stimulation of T cells (12, 13). It has thus been
suggested that targeting immunogenic tumor antigens to
DCs may represent an efficient means for induction of anti-
tumor immunity (14). Indeed, DC vaccination against ex-
perimental murine model tumors has given encouraging
results (15–20). However, to be effective, DC vaccination
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usually had to be initiated before or within a few days after
tumor cell transfer. Although in some of these studies tu-
mor antigens not exclusively expressed by the tumor had
been used (18–20), autoimmune side-effects had not been
observed. This lack of autoimmunity may be due to the
fact that only low CTL activities present for a relatively
short time were sufficient to control and clear these early
and small tumors without or before causing clinically ap-
parent autoimmune disease. In contrast, clinically estab-
lished tumors seem to require a strong and sustained CTL
response to guarantee complete remission of more sizeable
tumors (21). Although strong antitumor CTLs directed
against a unique and truly tumor-specific antigen may cure
the tumor without causing autoimmunity, this may be a se-
rious problem for CTL responses against antigens shared
between tumor cells and nonneoplastic cells. In the latter
case, it is important to evaluate the optimal conditions for
induction of tumor-specific CTLs by antitumor vaccina-
tion and whether a therapeutic window exists between in-
duction of tumor immunity and autoimmunity against so
far immunologically ignored self-antigens.
 
Materials and Methods
 
Mice and Viruses.
 
Mice were obtained from the Institut für
Labortierkunde (University of Zürich, Switzerland). Transgenic
mice expressing lymphocytic (L)CMV-GP (glycoprotein) under
the control of the rat insulin promotor (RIP-GP mice; reference
22), transgenic mice expressing the LCMV GP33 epitope in all
tissues (H8 mice; reference 23), and SM-LacZ mice expressing 
 
b
 
-
galactosidase under the control of the SM22
 
a
 
 promotor
(2126nlz; reference 24) have been previously described. Experi-
ments were carried out with age- (8–16 wk) and sex-matched
animals. The 
 
b
 
-galactosidase–recombinant vaccinia virus (VV-
LacZ) was provided by Dr. R. Drillien (Université Louis Pasteur,
Strasbourg, France) and grown and plaqued on BSC-40 cells.
 
Preparation and Peptide Pulse of DCs.
 
Generation of DCs from
bone marrow cultures of H8 and C57BL/6 mice has been de-
scribed (25). C57BL/6 DCs were pulsed with 
 
b
 
-galactosidase
peptide 
 
b
 
-gal 497–504 (reference 26) at a concentration of 10
 
2
 
6
 
 M
for 60 min at 37
 
8
 
C. Cells were washed three times with BSS and
injected intravenously in a volume of 0.5 ml of BSS.
 
Transplantation of Tumor Pieces and Monitoring of Tumor Growth.
 
The MC-GP cell line (27) and the EL4-LacZ cell line (26)
were described previously. Tumor cells in single-cell suspensions
were injected subcutaneously into the flanks of T cell–immu-
nodeficient mice (H-2
 
b
 
 RAG-1
 
2
 
/
 
2
 
). Growing tumor pieces were
dissected into small tumor pieces of 2 
 
3 
 
2 
 
3 
 
2 mm containing
 
z
 
2–5 
 
3
 
 10
 
6
 
 tumor cells and transplanted into the flanks of naive
recipient mice. Tumor size was assessed twice per week, and the
animals were killed when the tumor volume reached 
 
z
 
7 cm
 
3
 
.
Tumor volume was calculated by the formula V
 
 5 p 3
 
 abc/6,
where a, b, and c are the orthogonal diameters. Tumor cells were
checked before transplantation and at the end of each experiment
for tumor antigen expression.
 
Cytotoxicity Assays.
 
Spleen cells (4 
 
3
 
 10
 
6
 
 per well) from
primed mice were restimulated for 5 d in 24-well tissue culture
plates with 2 
 
3
 
 10
 
6
 
 
 
b
 
-gal 497–504-pulsed, irradiated (3,000 rads)
spleen cells in IMDM supplemented with 10% FCS, penicillin/
streptomycin, and 0.001 M 2-ME. Restimulated spleen effector
cells from one well were resuspended in 1 ml of MEM/2% FCS,
and threefold serial dilutions were made (indicated as dilution of
culture). EL-4 cells were pulsed with 
 
b
 
-gal 497–504 (10
 
2
 
6
 
 M; 1.5 h
at 37
 
8
 
C) and used in a standard 5-h 
 
51
 
Cr-release assay. Unlabeled
EL-4 cells served as controls.
 
Cell Rejection Assay.
 
To monitor DC-induced CTL activity
directly in vivo, naive or SM-LacZ mice primed with 2 
 
3
 
 10
 
5
 
b
 
-gal 497–504-pulsed DCs on days 0 and 2 were adoptively trans-
fused with 
 
b
 
-gal 497–504-pulsed splenocytes on day 8. 
 
b
 
-gal
497–504-pulsed splenocytes were labeled with a high intensity of
CSFE (5- and 6-carboxyfluorescein diacetate succinimidyl ester;
Molecular Probes, Inc.) fluorescence, whereas unpulsed control
cells were labeled with a low intensity of CSFE fluorescence. 4 
 
3
 
10
 
7
 
 cells from each preparation were transferred intravenously
into naive or DC-primed mice, and the percentage of CSFE-pos-
itive cells in PBL was determined by FACS
 
®
 
 analysis after 24 h.
Erythrocytes were lysed with FACS lysis solution (Becton Dick-
inson), and the cell suspensions were analyzed on a FACScan™
flow cytometer (Becton Dickinson).
 
Measurement of Blood Glucose.
 
The glucose concentration in
blood obtained from a tail vein was measured using an ELITE he-
moglucometer (Bayer AG). Mice were considered diabetic with
values 
 
.
 
14 mM at two consecutive measurements.
 
Immunohistology.
 
Freshly removed organs were immersed in
Figure 1. DC treatment of peripherally growing MC-GP tumors leads
to diabetes in RIP-GP mice. Mice with established MC-GP tumors (di-
ameter .5 mm on day 14) were used for immunotherapy. Closed sym-
bols indicate blood glucose levels; open symbols represent tumor volume
in three individual mice at the indicated time points after beginning of
treatment with H8-DC. (A) Tumor growth and blood glucose levels in
untreated RIP-GP mice. (B) Successful treatment of MC-GP tumors
with GP33-expressing H8-DCs in RIP-GP mice is accompanied by rap-
idly developing hyperglycemia. Mice were immunized intravenously
with 2 3 105 H8-DCs on days 0, 2, 10, and 12. (C) Development of hy-
perglycemia in RIP-GP mice after repetitive intravenous immunization
with 2 3 105 H8-DCs on days 0, 2, 10, and 12. Results from one of three
comparable experiments are shown. 
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HBSS and snap-frozen in liquid nitrogen or fixed in 4% buffered
formalin and subsequently embedded in paraplast. Frozen tissue
sections were cut in a cryostat and fixed in acetone for 10 min.
Sections were incubated with anti–mouse mAb against CD8
 
1
 
cells (YTS169.4.2; reference 28), followed by goat anti–rat Ig
(Caltag Labs.) and alkaline phosphatase–labeled donkey anti–goat
Ig (Jackson ImmunoResearch Labs.). Endothelial cells and
smooth muscle cells were stained on deparaffinized sections using
rabbit anti–von Willebrand factor (DAKO A/S) or anti–smooth
muscle actin (clone 1A4; Sigma Chemical Co.), respectively. Al-
kaline phosphatase was visualized using AS-BI phosphate/new
fuchsin. Sections were counterstained with hemalum.
 
Results
 
Development of Autoimmune Diabetes as a Consequence of
Curative Tumor Immunity.
 
We have previously shown that
both the strength of the initial activation and the mainte-
nance of CTL activity by repetitive DC immunization are
important parameters for the induction of an autoimmune
disease via DCs (29). Correspondingly, a single immuniza-
tion with DCs is usually not sufficient to cure an established
and peripherally growing tumor; maintenance of CTL activ-
ity by repetitive DC immunization is required to control and
to eventually cure such a tumor (21). In a first set of experi-
ments, we evaluated the consequences of an antitumor re-
sponse against a model tumor antigen that is also expressed
on strictly peripheral pancreatic 
 
b
 
 islet cells. RIP-GP mice
express the GP of LCMV exclusively in pancreatic 
 
b
 
 islet
cells, where the neo–self-antigen is immunologically ignored
unless mice are infected with LCMV (22) or immunized
with GP-expressing DCs (29) to induce an appropriate anti–
LCMV-GP–specific immune response in secondary lym-
 
phoid organs. LCMV-GP was also transfected into fibrosar-
coma cell line MC57 (MC-GP; references 21 and 27). Small
pieces of MC-GP tumors (2 
 
3 
 
2 
 
3
 
 2 mm) were implanted
subcutaneously into RIP-GP mice, and therapeutic treat-
ment was started when successful tumor growth could be
determined by palpation (tumor diameter 
 
$
 
5 mm, usually
around day 14 after transplantation). Normal C57BL/6 mice
do not generate an anti–LCMV-GP response after transplan-
tation of MC-GP tumor pieces because tumor cells do not
reach lymphoid organs (21). Similarly, in RIP-GP mice,
MC-GP tumor pieces grew without inducing a specific im-
mune response, and the mice remained normoglycemic (Fig.
1 A). When treatment of mice was started 14 d after trans-
plantation with repetitive injection of 2 
 
3
 
 10
 
5
 
 DCs constitu-
tively expressing the immunodominant CTL epitope of
LCMV-GP (H8-DC), the treatment also led to efficient tu-
mor control in RIP-GP mice (Fig. 1 B). However, these re-
cipients rapidly developed diabetes with an early onset and a
severe disease outcome (30% of the mice died before day 21;
Fig. 1 B), comparable to or slightly more severe than that of
RIP-GP mice without MC-GP tumors treated with the same
protocol (10% of the mice died before day 21; Fig. 1C).
Importantly, RIP-GP mice also became diabetic when the
tumor treatment was started on day 5 after transplantation,
requiring lower doses of H8-DC to achieve tumor control
(Table I). Table I summarizes all experiments, showing that
in RIP-GP mice, antitumor treatment with H8-DC was ac-
companied by autoimmune diabetes in every case where CTL
activity was maintained for a prolonged period of time. Ap-
parently, in this model situation using a tumor antigen with
known distribution, there was no window for curative tumor
immunity without the side-effect of autoimmune diabetes.
 
Table I.
 
Rejection of Established Fibrosarcomas and Development of Diabetes in RIP-GP and C57BL/6 Mice after Curative Treatment with 
H8-DCs
 
Recipient mice/tumor Treatment
 
*
 
Tumor control
 
‡
 
Incidence of diabetes
 
§
 
Experiment 1: treatment started on day 14 (established, palpable tumors only)
RIP-GP/MC-GP 2 
 
3
 
 10
 
5
 
 H8-DCs 10/10 10/10
RIP-GP/none 2 
 
3
 
 10
 
5
 
 H8-DCs — 10/10
C57BL/6/MC-GP 2 
 
3
 
 10
 
5
 
 H8-DCs 10/10 0/10
RIP-GP/MC-GP None 0/6 0/6
Experiment 2: treatment started on day 5 (tumors not yet palpable, tumor take 80%) 
RIP-GP/MC-GP 2 
 
3
 
 10
 
4
 
 H8-DCs 7/10 10/10
RIP-GP/none 2 
 
3
 
 10
 
4
 
 H8-DCs — 4/4
C57BL/6/MC-GP 2 
 
3
 
 10
 
4
 
 H8-DCs 6/10 0/10
RIP-GP/MC-GP None 1/5 0/5
 
*
 
In experiment 1, mice with established MC-GP tumors (diameter 
 
.
 
5 mm on day 14) were intravenously immunized repetitively with 2 
 
3
 
 10
 
5
 
H8-DCs on days 14, 16, 24, and 26 after transplantation or were left untreated. In experiment 2, mice were treated before tumor growth was detect-
able by palpation with 2 
 
3
 
 10
 
4 
 
H8-DCs on days 5, 7, 15, and 17 after transplantation. Tumor take in experiment 2 was 80%, as tumors grew in four
out of five untreated RIP-GP mice. 
 
‡
 
Tumors with a volume of 
 
,
 
1 cm
 
3
 
 until day 38 (experiment 1) or day 29 (experiment 2) after transplantation were counted as controlled. Numbers
indicate the proportion of tumors controlled per tumors tested.
 
§
 
Mice were scored diabetic with blood glucose 
 
.
 
14 mM on two consecutive measurements.  
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Figure 2. Immune responses against the b-galactosi-
dase antigen in SM-LacZ mice. (A) SM-LacZ mice or
control C57BL/6 mice (B6) were intravenously immu-
nized with 2 3 106 pfu of VV-LacZ. 8 d later, spleen
cells were restimulated in vitro for 5 d with peptide-
labeled, irradiated spleen cells. Specific lysis was mea-
sured on b-gal 497–504-labeled EL4 target cells (closed
symbols) or on EL4 cells without peptide (open sym-
bols). Data from two individual mice per group are
shown. (B) Rejection of b-gal 497–504-pulsed spleen
cells. Naive or primed SM-LacZ mice or C57BL/6
control mice (intravenous injection of 2 3 105 b-gal
497–504-pulsed DCs) were intravenously transfused
with 4 3 107 b-gal 497–504-pulsed spleen cells (b-
gal1) labeled with a high fluorescence intensity and
with 4 3 107 control spleen cells labeled with a low
fluorescence intensity (ctrl). 24 h after adoptive transfer,
PBLs were analyzed by FACS® analysis. Results are
from one of two comparable experiments.
 
Induction of Severe Cardiovascular Autoimmune Disease during
Antitumor Treatment with DCs.
 
To evaluate the close link-
age between tumor therapy and the possible induction of
autoimmunity against so far immunologically ignored pe-
ripheral self-antigens by DC treatment, we used a second tu-
mor model. A transgenic mouse line was established that ex-
presses the 
 
b
 
-galactosidase antigen in cardiomyocytes of the
right ventricle and in arterial smooth muscle cells (SM-LacZ
mice; reference 24). Comparable to the RIP-GP mice de-
scribed above, SM-LacZ mice possess a normal immune re-
activity against 
 
b
 
-galactosidase. This is shown by the fact
that the 
 
b
 
-galactosidase–specific CTL response after immu-
nization with recombinant 
 
b-galactosidase–expressing vac-
cinia virus (VV-LacZ) was similar in SM-LacZ and control
C57BL/6 mice (Fig. 2 A). Furthermore, SM-LacZ mice
rapidly rejected b-gal 497–504-pulsed spleen cells after
priming with DCs exogenously loaded with b-gal 497–504
with kinetics similar to those of control C57BL/6 mice (Fig.
2 B). Repetitive priming of SM-LacZ mice with DCs pre-
senting b-galactosidase peptide caused vascular immunopa-
thology with strong lymphocytic infiltration in small and
medium-sized arteries and in the right ventricle, whereas re-
petitive DC treatment of nontransgenic littermates resulted
in a mild, nonspecific lymphocyte infiltration in the liver but
was not associated with cardiovascular immunopathology.
Furthermore, immunization of SM-LacZ mice with DCs
pulsed with an irrelevant peptide did not lead to specific
anti–b-galactosidase CTL activity and again induced only a
mild, nonspecific liver infiltration (Ludewig, B., unpublished
results). In naive SM-LacZ mice, specific CTL reactivity was
not detectable (Fig. 2 B), and lymphocytes did not infiltrate
the right heart muscle or transgene-positive arteries (not
shown). Thus, in SM-LacZ mice, the b-galactosidase trans-
gene is immunologically ignored, despite the widespread ex-
pression in the vascular system.
Tumor cells used in this set of experiments were EL-4
thymoma cells expressing b-galactosidase (EL4-LacZ; refer-
ence 26). EL4-LacZ tumor cells process and present b-galac-
tosidase peptides on MHC class I antigens; CTLs from
C57BL/6 mice primed with VV-LacZ and restimulated
Figure 3. Characterization of EL4-LacZ tumor cells and immunother-
apy of EL4-LacZ tumors in SM-LacZ mice. (A) EL4-LacZ (d) and EL4
cells with (j) or without (h) peptide b-gal 497–504 were used in vitro
as targets in a 51Cr-release assay. Effector cells were b-gal 497–504-restim-
ulated spleen cells from C57BL/6 mice infected with 2 3 106 pfu VV-
LacZ. (B) 2 3 107 EL4-LacZ tumor cells were injected subcutaneously
into the flanks of C57BL/6 mice. 8 d later, splenocytes were restimulated
in vitro using irradiated, b-gal 497–504-pulsed spleen cells for 5 d, and
the CTL activity was determined in a 51Cr-release assay on b-gal 497–
504-labeled EL4 target cells (closed symbols) or on EL4 cells without
peptide (open symbols). (C) Small pieces of EL4-LacZ tumors were im-
planted subcutaneously in the flanks of SM-LacZ mice on day 1, and tu-
mor growth was assessed at the indicated time points. (D) SM-LacZ mice
received small EL4-LacZ tumor pieces as in C and were treated from day
0 repetitively by intravenous injection with 3–5 3 105 b-gal 497–504-
pulsed DCs. Arrows, day of injection. Numbers indicate the proportion
of tumor rejection (or tumor growth) in tumors tested. Results from one
of two comparable experiments are shown.799 Ludewig et al.
with b-gal 497–504 specifically lyse EL4-LacZ cells (Fig. 3
A). Furthermore, EL4-LacZ tumor cells were immuno-
genic after subcutaneous injection into naive recipients,
leading to induction of b-galactosidase–specific CTLs (Fig.
3 B). After subcutaneous injection of up to 2 3 107 tumor
cells in suspension, tumor growth was not detectable, indi-
cating the high immunogenicity and efficiency of the CTL
response against these tumor cells. However, as for MC-
GP tumors, tumors grew rapidly in naive SM-LacZ mice
after subcutaneous transplantation of small, solid EL4-LacZ
tumor pieces containing 2–5 ´ 106 cells (Fig. 3 C). Repeti-
tive treatment of SM-LacZ mice with growing EL4-LacZ
tumors using DCs pulsed with b-gal 497–504 efficiently
controlled tumor growth; it caused tumor eradication in
50% of the mice and significantly delayed tumor growth in
the other 50% (Fig. 3 D). However, in mice responding
with either complete tumor remission or with reduced tu-
mor growth, this treatment was accompanied by strong
lymphocytic infiltrates in the right ventricle (Fig. 4 A) that
consisted mainly of CD81 T cells (Fig. 4 C). In the lungs,
DC-induced autoimmune lesions were found associated
with pulmonary arteries characterized by strong lympho-
cyte aggregations in the adventitia and media (Fig. 4 B) and
increased lymphocyte adhesion to the inflamed endothe-
lium (Fig. 4 B, inset). Also, in the lesions of the pulmonary
arteries, CD81 T cells dominated the early infiltrate (Fig. 4
D). Strong tumor infiltrates consisting mainly of CD81 T
cells were found in tumors responding to the therapy with
complete remission (Fig. 4 E). In most untreated SM-LacZ
mice, an anti–b-galactosidase immune response was not in-
duced by the transplanted tumor growing in the periphery;
T cells did not infiltrate the right ventricle (Fig. 4 G) or
pulmonary arteries (Fig. 4 H). However, in two out of five
untreated SM-LacZ mice, tumors were growing consider-
ably more slowly, and some tumor-infiltrating CTLs could
be detected (Fig. 4 I). In these mice, few CD81 T cells in-
filtrated pulmonary arteries, but none were found in the
right ventricle (not shown), indicating that the tumor cells
alone had induced both limited tumor immunity and mild
autoimmunity.
When SM-LacZ mice with tumors were treated with
b-galactosidase peptide–pulsed DCs, a dilated cardiomyopa-
thy developed. 3–4 wk after highly repetitive antitumor
treatment with DCs, the right ventricle wall was dilated
(Fig. 4 J), and cardiomyocytes had been largely destroyed
and replaced by fibrotic tissue (Fig. 4 J, inset). Fig. 4 K
shows the macroscopic pathology of dilated hearts from
SM-LacZ mice after curative tumor treatment with b-galac-
tosidase peptide–pulsed DCs in comparison with hearts
from untreated control mice.
Taken together, these results show that previously ig-
nored self-antigens, such as LCMV-GP in RIP-GP mice or
b-galactosidase in SM-LacZ mice, may serve as target anti-
gens for vaccination using antigen-expressing DCs. How-
ever, potentially harmful autoimmune responses against
these self-antigens are induced by DC treatment when a
strong and sustained CTL activity is necessary to eliminate
the tumor. Depending on the tumor size and the corre-
spondingly needed prolonged maintenance of antitumor/
antiself CTL activity, severe and even lethal autoimmunity
may develop before tumor growth is controlled.
Discussion
The above results indicate an important if not crucial
problem of immunotherapeutic treatment of tumors: if tu-
mors can be controlled and even eliminated by CTLs and if
tumor epitopes are also expressed by other peripheral tissues
exclusively outside the immune system, is there a window
in which specifically activated CTLs reject the tumor but do
not induce autoimmune disease? In our two examples of
shared tumor antigens, effective immunization against the
tumor is paralleled by induction of autoimmunity to a set of
self-antigens that so far had been immunologically ignored
in the periphery. These results indicate that a window for
the delicate balance between induction of an effective anti-
tumor immunity and a possible simultaneous autoimmune
pathogenesis is either very small or nonexistent when the
antitumor response is directed against such antigens that are
not strictly tumor specific.
Immunological Ignorance as an Avenue for Therapeutic Tumor
Immunotherapy. It is conceivable that therapeutic tumor
immunotherapy is most promising when tumor antigen–
specific T cells of high avidity have not been centrally or
peripherally deleted, i.e., the antigen has stayed outside of
lymphatic tissues and therefore has been immunologically
ignored. It appears that immunological ignorance of anti-
gens strictly expressed in peripheral tissues is a function of
antigen distribution and expression level. For example, in
transgenic model situations with low levels of antigen ex-
pression exclusively in pancreatic b islets (22, 30) or solely
in cells of the cardiovascular system, this report shows that
the antigens are immunologically ignored. In contrast, high
levels of self-antigen expression leads either to central (31,
32) or peripheral tolerance (33, 34). Similarly, tumor anti-
gens can be either immunologically ignored when expressed
at low levels in the periphery (21, 35, 36) or induce a CTL
immune response when they are expressed abundantly and
reach local secondary lymphoid organs (37). It has been sug-
gested that presentation of such tumor antigens by bone
marrow–derived APCs in secondary lymphoid organs may
lead to tumor-specific T cell unresponsiveness, particularly
in the CD41 T cell compartment (38, 39). In a study with
patients with metastatic melanoma, Lee et al. (40) found
that in 1 out of 11 patients, tumor-specific CD81 T cells
might also become unresponsive. From these examples, it is
not clear whether such tumor-specific CD81 and/or CD41
T cell unresponsiveness is the general rule that leads to a
failure of tumor immunity or rather the exception.
We favor the view that central and/or peripheral toler-
ance mechanisms usually do not exist against peripheral tu-
mor antigens of sarcomas and carcinomas and that the ma-
jority of tumor and self-antigens are immunologically
ignored. This is supported by the findings that high fre-
quencies of tumor-specific CTLs exist in both tumor pa-
tients and healthy individuals (41, 42) and that antitumor800 Dendritic Cell–induced Autoimmunity and Tumor Immunity
Figure 4. Immunohistological analysis of heart and lung tissue in SM-LacZ mice transplanted with EL4-LacZ tumors and treated repetitively with 3–5 3
105 b-gal 497–504-pulsed DCs (A–F, J, K) or left untreated (G–I). Formalin-fixed and paraffin-embedded sections of heart (A) and lung (B) tissue were
stained for smooth muscle actin from a DC-treated SM-LacZ mouse on day 11 after immunization. The inset in A is a magnification of the boxed area in A
showing a strong lymphocytic infiltrate between heart muscle cells (arrows) and in the interstitium surrounding coronary arteries (arrowhead). The inset in B
is a magnification of the boxed area in B stained for factor VIII showing the strongly increased adhesion of lymphocytes to the inflamed endothelium (arrows)
and a strong infiltrate of lymphocytes in the arterial adventitia. Staining for CD81 lymphocytes in the heart (C), lung (D), and tumor (E and F) of a DC-
treated SM-LacZ mouse on day 11. (E) Strong CTL infiltration in a regressing tumor and (F) infiltration of CTL in a growing tumor. Arrows in F indicate
tumor infiltrating lymphocytes; the arrowhead indicates an artery not infiltrated by CD81 lymphocytes. In untreated SM-LacZ mice with transplanted EL4-
LacZ tumors, CD81 lymphocytes were not detected in the right ventricle wall (G) or pulmonary arteries (H) but were occasionally found in small numbers
in the tumor tissue (I, arrow). (J) Dilated right ventricle in SM-LacZ mouse 25 d after repetitive immunization with b-gal 497–504-pulsed DCs. Inset is a
magnification of the boxed area in J showing infiltration with mononuclear cells, fibrotic tissue, and remaining intact cardiomyocytes. (K) Macroscopic pa-
thology of two hearts from DC-treated SM-LacZ mice on day 25 (top row) in comparison with two control hearts from untreated animals without tumors
(bottom row). Ruler indicates the size in millimeters. Original magnifications: A and B, 350; J, 320; insets in A, B, and J, 3200; C–I, 3100.801 Ludewig et al.
CTLs may be of high avidity (43). Most importantly, the
potent (unimpaired) function of antitumor T cells can be
observed in melanoma patients suffering from vitiligo,
where tumor-specific T cells mediate autoimmune depig-
mentation (8). It is therefore important for tumor immuno-
therapy to use as targets antigens that have been previously
immunologically ignored. However, immunization with,
for example, DCs efficiently presenting so far immunologi-
cally ignored shared tumor antigens will cause rejection of
tumors but will also lead to autoimmunity. The two exper-
imental systems used in this report model such a shared nat-
ural tumor situation: immune surveillance against poten-
tially immunogenic tumor antigens fails because the tumor
antigens are immunologically ignored for too long. Conse-
quently, neither autoimmunity nor an antitumor response
was induced. DC priming controlled the tumor and elic-
ited a severe autoimmune response against pancreatic b-islet
cells or cells of the cardiovascular system that was life
threatening. Of course, immunotherapy with antigens de-
rived from less essential organs may cause transient and less
severe disease.
Implications for the use of DCs in Antitumor Immunotherapy.
Some experimental murine tumors express target anti-
gens restricted solely to the tumor and can therefore be
efficiently cured without inducing autoimmune phenom-
ena using, for example, DCs (15–17). In cases in which
non–tumor-restricted antigens are used, autoimmune se-
quelae are probably not observed when the requirements
for immune activity are rather low and tumor elimination
is achieved before autoimmune symptoms appear (18–20).
This probably depends largely on the relative size of the tu-
mor versus the size and importance of the autoimmune tar-
get, as well as on the relative precursor and effector T cell
frequencies. Furthermore, it is possible that tumor cells
may provide certain factors compensating for the lack of
healthy tissue that is destroyed during curative antitumor
treatment (e.g., in the model study of Speiser et al. [36],
where insulin-producing insulinoma cells compensate for
the destruction of pancreatic b-islet cells during antitumor
treatment).
Under certain experimental transgenic conditions, high-
avidity CTLs reactive for both tumor and self-antigens may
be deleted. The remaining appropriately activated low-avid-
ity CTLs may provide protection against subsequent tumor
challenges but may not suffice to provoke autoimmunity
(44). Alternatively, it is possible that CD41 T cells alone me-
diate tumor immunity. For example, it has been shown in a
transgenic mouse model that CD41 T cell–mediated antitu-
mor immune responses do not lead to obvious autoimmune
sequelae when a retroviral tumor antigen is expressed in
normal lymphoid tissues (45). However, it is questionable
whether CD41 T cell–mediated antitumor immune re-
sponses alone may be sufficient to cure rapidly growing tu-
mors in the periphery via adoptive immunotherapy.
As stated, in situations where self- and tumor-reactive,
high-avidity CTLs are not centrally or peripherally deleted
and the antigens are immunologically ignored, such as in
RIP-GP or SM-LacZ mice, strong antitumor responses that
are also directed against self-antigens will eventually cause
autoimmunity. This has also been observed in nontransgenic
situations when mice were immunized with the melanoma
antigen gp75/tyrosinase-related protein 1, leading to mainly
T helper–mediated protection against tumor challenge and
also to mild depigmentation (46, 47). Similarly, in clinical
studies, induction of autoimmune depigmentation has been
associated with a good prognosis for melanoma patients, in-
dicative of successful control of the tumor by the immune
system (8). Recently, it has been shown that paraneoplastic
cerebellar degeneration (PCD) is probably mediated by
CTLs specific for tumor antigens present on gynecological
tumors and in neuronal tissue (48). Interestingly, PCD-asso-
ciated gynecological tumors have been documented to re-
gress with the onset of autoimmune neurological disease (9).
The clinical consequences of autoimmune reactions against
normal melanocytes causing vitiligo during melanoma treat-
ment or a strong autoimmune reaction against organs where
the loss of function can be substituted, e.g., with insulin for
damage of pancreatic b islet cells, are acceptable during im-
munotherapeutic antitumor treatment. In contrast, other au-
toimmune diseases, such as reactions against cells in the
cardiovascular system or neuronal tissue, may impose limita-
tions on antitumor therapy with DCs using antigens also ex-
pressed by cells in vital organs.
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